ReviewClinical reviews in allergy & immunology2025
Towards a Multi-omics Understanding of Anaphylaxis: Insights into Pathogenesis and Biomarker Identification.
Review in Clinical reviews in allergy & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiota and anaphylaxis: emerging insights into immune regulation and clinical implications.Current opinion in allergy and clinical immunology · 2026Review
- Gastrointestinal adverse events associated with tirzepatide: A bibliometric and pharmacovigilance analysis.PloS one · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Anaphylaxis is a severe, life-threatening hypersensitivity reaction that presents significant challenges in both clinical practice and scientific research. While individual omics studies have provided valuable insights into the genetic predisposition, immune dysregulation, and metabolic alterations associated with anaphylaxis, a comprehensive understanding of its full pathophysiology remains elusive. Multi-omics integration, which combines genomics, epigenomics, transcriptomics, proteomics, and metabolomics, has the potential to uncover novel mechanisms, biomarkers, and therapeutic targets. However, studies employing comprehensive multi-omics approaches in anaphylaxis are still limited. This review of 107 studies published between 2000 and 2024-including genomics (43), metagenomics (2), epigenomics (2), transcriptomics (20), proteomics (26), and metabolomics (14)-synthesizes findings from existing single-omics studies on human anaphylaxis, identifies key interconnections across omics layers, and underscores the critical need for large-scale, integrative research. Advancing this type of research is essential to advance our understanding of anaphylaxis, improve risk prediction, and enhance both diagnosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.